1. Home
  2. PIII vs MDXH Comparison

PIII vs MDXH Comparison

Compare PIII & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo P3 Health Partners Inc.

PIII

P3 Health Partners Inc.

HOLD

Current Price

$11.31

Market Cap

37.5M

Sector

Health Care

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.43

Market Cap

41.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PIII
MDXH
Founded
2015
2003
Country
United States
Belgium
Employees
320
N/A
Industry
Medical/Nursing Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.5M
41.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PIII
MDXH
Price
$11.31
$0.43
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$9.00
$7.67
AVG Volume (30 Days)
72.5K
758.2K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.67
$30.78
Revenue Next Year
$2.36
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.45
52 Week High
$16.89
$5.33

Technical Indicators

Market Signals
Indicator
PIII
MDXH
Relative Strength Index (RSI) 53.98 18.95
Support Level $10.12 N/A
Resistance Level $14.21 $3.79
Average True Range (ATR) 1.23 0.05
MACD -0.40 0.04
Stochastic Oscillator 32.89 11.12

Price Performance

Historical Comparison
PIII
MDXH

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: